Previous 10 | Next 10 |
PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
Conference Call and Webcast to be Held at 2:00 P.M CET/8:00 A.M. EDT on March 29, 2023 PARIS and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...
Nanobiotix ( NASDAQ: NBTX ) said the first patient in the U.S. was randomized in a global phase 3 trial of NBTXR3 to treat elderly patients with locally advanced head and neck squamous cell carcinoma ((LA-HNSCC)) who are ineligible for platinum-based chemotherapy. NBTXR3 activated by ...
Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and Asia NANORAY-312 now has sites activated across 80 sites globally Phase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024 ...
Nanobiotix ( NASDAQ: NBTX ) on Wednesday announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont. The termination is effective from December 20th, 2022. On the termination date of the contract, 22,118 shares and ...
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Paris, France, December 8, 2022 Market: Euro...
PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibi...
Data show that radiotherapy-activated NBTXR3 was feasible and well tolerated in the complete dose escalation part of a Study 2019-1001, a phase 1 evaluation of NBTXR3 for patients with locally advanced pancreatic adenocarcinoma The recommended phase 2 dose for radiotherapy-activated N...
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 08:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...